Optimizing combination rifampin therapy for staphylococcal osteoarticular infections

Joint Bone Spine

Volumn 80, Issue 1, 2013, Pages 11-17

  Coiffier, Guillaume ^a,b   Albert, Jean David ^a,b   Arvieux, Cédric ^b   Guggenbuhl, Pascal ^a,b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotics; Osteoarticular infections; Rifampicin staphylococcus; Septic arthritis

Indexed keywords

CEFAZOLIN; CEPHALOSPORIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; ISOPENICILLIN N; LINEZOLID; MINOCYCLINE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INFECTION; MONOTHERAPY; NONHUMAN; OSTEOARTICULAR INFECTION; SHORT SURVEY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; BIOFILMS; DRUG THERAPY, COMBINATION; HUMANS; INFECTION; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 84872856797     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.09.008     Document Type: Short Survey

References (62)

1. Recommandations de pratique clinique. Infections ostéo-articulaires sur matériel (prothèse, implant, ostéosynthèse). Med Mal Infect 2009;39:745-74.
2. Spondylodiscites infectieuses primitives, et secondaires à un geste intra-discal, sans mise en place de matériel. Texte court. Med Mal Infect 2007;37:554-72.
3. Mathews C.J., Weston V.C., Jones A., et al. Bacterial septic arthritis in adults. Lancet 2010, 375:846-855.
4. Forrest G.N., Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010, 23:14-34.
5. Campbell E.A., Korzheva N., Mustaev A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001, 104:901-912.
6. Monographie de « RIFADINE 300MG GEL ». Pharmacocinétique. Vidal 2011. Avaible from: URL: . http://www.vidal.fr/Medicament/rifadine-14476.htm.
7. Boselli E., Allaouchiche B. Diffusion in bone tissue of antibiotics. Presse Med 1999, 28:2265-2276.
8. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
9. Gilbert P., Collier P.J., Brown M.R. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother 1990, 34:1865-1868.
10. Ellington J.K., Harris M., Hudson M.C., et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006, 24:87-93.
11. Murphy C.K., Karginova E., Sahm D., et al. In vitro activity of novel rifamycins against gram-positive clinical isolates. J Antibiot (Tokyo) 2007, 60:572-576.
12. Sanginur R., St Denis M., Ferris W., et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006, 50:55-61.
13. Castanheira M., Watters A.A., Mendes R.E., et al. Occurrence and molecular caracterization of fusidic acid resistance mechanisms among Staphylococcus spp. Fron European countries (2008). J Antimicrob Chemother 2010, 65:1353-1358.
14. Stengel D., Bauwens K., Sehouli J., et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001, 1:175-188.
15. Senneville E., Joulie D., Legout L., et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011, 53:334-340.
16. Zimmerli W., Widmer A.F., Blatter M., et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279:1537-1541.
17. Barberan J., Aguilar L., Gimenez M.J., et al. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int J Antimicrob Agents 2008, 32:154-157.
18. Berdal J.E., Skråmm I., Mowinckel P., et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect 2005, 11:843-845.
19. Drancourt M., Stein A., Argenson J.N., et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993, 37:1214-1218.
20. Senneville E., Yazdanpanah Y., Cazaubiel M., et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001, 48:927-930.
21. Perlroth J., Kuo M., Tan J., et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus Infections. A systematic review of the literature. Arch Intern Med 2008, 168:805-819.
22. Nijland H.M., Ruslami R., Suroto A.J., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007, 45:1001-1007.
23. Van der Auwera P., Klastersky J. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus. Rev Infect Dis 1983, 5:S509-S514.
24. Brandt C.M., Rouse M.S., Tallan B.M., et al. Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus. Antimicrob Agents Chemother 1994, 38:2191-2193.
25. Zinner S.H., Lagast H., Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981, 144:365-371.
26. Norden C.W. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 1983, 5:S491-S494.
27. Van der Auwera P., Joly P. Comparative in vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus. J Antimicrob Chemother 1987, 19:313-320.
28. Lowy F.D., Chang D.S., Lash P.R. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother 1983, 23:932-934.
29. Bayer A.S., Morrison J.O. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984, 26:220-223.
30. Rose W.E., Poppens P.T. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009, 63:485-488.
31. Karchmer A.W., Archer G.L., Dismukes W.E. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983, 5:S543-S548.
32. Riedel D.J., Weekes E., Forrest G.N. Addition of rifampin to standard therapy for treatment of native valve Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2008, 52:2463-2467.
33. Daver N.G., Shelburne S.A., Atma R.L., et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007, 54:539-544.
34. Schaller C., Lesens O., Hansmann Y., et al. Faut-il différer l'introduction de la rifampicine lors d'une bactériémie prolongée à Staphylococcus aureus ?. Med Mal Infect 2004, 34:S130-S169.
35. Levine D.P., Fromm B.S., Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
36. Jones R.N., Mendes R.E., Sader H.S., et al. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) Gram-positive organisms collected in the United States. Clin Infect Dis 2011, 52:S477-S486.
37. Lemaire S., Van Bambeke F., Pierard D., et al. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparaison with linezolid and clindamycin. Clin Infect Dis 2011, 52:S493-S503.
38. Monographie de « FUCIDINE 250MG CP PELLIC ». Pharmacocinétique. Vidal 2011. Avaible from: URL: . http://www.vidal.fr/Medicament/fucidine-7199.htm.
39. Farber B.F., Yee Y.C., Karchmer A.W. Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci. Antimicrob Agents Chemother 1986, 30:174-175.
40. Foldes M., Munro R., Sorrell T.C. In vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1983, 11:21-26.
41. Aboltins C.A., Page M.A., Buising K.L., et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007, 13:586-591.
42. Drancourt M., Stein A., Argenson J.N., et al. Oral treatment of Staphylococcus sp infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997, 39:235-240.
43. Ho J.L., Klempner M.S. In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 1986, 4:133-138.
44. Watanakunakorn C. Effects of clindamycin in combination with rifampicin on clindamycin-susceptible and clindamycin-resistant Staphylococcus aureus. J Antimicrob Chemother 1985, 16:335-339.
45. Monographie de « DALACINE 600mg sol inj ». Pharmacocinétique. Vidal 2011. Available at . http://www.vidal.fr/Medicament/dalacine-4770.htm.
46. El Samad Y., Havet E., Bentayeb H., et al. Treatment of osteoarticular infections with clindamycin in adults. Med Mal Infect 2008, 38:465-470. (In French).
47. Zeller V., Dzeing-Ella A., Kitzis M.D., et al. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010, 54:88-92.
48. De Coppet H., Senneville E., Migaud H., et al. Comparaison des associations rifampicine-clindamycine et rifampicine-ofloxacine dans le traitement des infections ostéo-articulaires staphylococciques sur matériel orthopédique. Med Mal Infect 2009, 39:S53.
49. Harvey R.J. Antagonistic interaction of rifampicin and trimethoprim. J Antimicrob Chemother 1978, 4:315-327.
50. Hackbarth C.J., Chambers H.F., Sande M.A. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 1986, 9:611-613.
51. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytised MRSA. J Infect Chemother 2007, 13:141-146.
52. Monograph for " BACTRIM FORTE cp" . Pharmacocinétique. Vidal 2011. Avaible from: URL: . http://www.vidal.fr/Medicament/bactrim_forte-1850.htm.
53. Norden C.W., Keleti E. Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob Agents Chemother 1980, 17:591-594.
54. Euba G., Murillo O., Fernández-Sabé N. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009, 53:2672-2676.
55. Steenbergen J.N., Mohr J.F., Thorne G.M. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009, 64:1130-1138.
56. Leite B., Gomes F., Teixeira P. In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms. Curr Microbiol 2011, 63:313-317.
57. Forrest G.N., Donovan B.J., Lamp K.C., et al. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother 2008, 42:213-217.
58. Burdette S.D. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine. Spine J 2009, 9:e5-e8.
59. Legout L., Valette M., Dezeque H., et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?. J Antimicrob Chemother 2010, 65:2224-2230.
60. Nguyen S., Pasquet A., Legout L., et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009, 15:1163-1169.
61. Darley E.S., MacGowan A.P. Antibiotic treatment of gram-positive bone and joint infections. Antimicrob Chemother 2004, 53:928-935.
62. Ruhe J.J., Monson T., Bradsher R.W., et al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005, 40:1429-1434.